Drug and device development and commercialisation services company ICON plc (NASDAQ:ICLR) revealed on Wednesday that it has completed the acquisition of MedPass International.

Headquartered in Paris, MedPass International is a medical device CRO, regulatory and reimbursement consultancy.

The company has served more than 1,000 medical device companies, from start-ups to multi-nationals, and has contributed to the development of hundreds of innovative devices including a number of breakthrough technologies. It specialises in medical device development and market access.

Through the acquisition, ICON enhances its Medical Device and Diagnostic Research Services, acquires new regulatory and clinical capabilities in Europe and broadens its medical device footprint and staff headcount across Europe.

The integration of MedPass International's services brings expertise in complex class 3 medical devices, interventional cardiology and structural heart devices.

Financial details of the deal were not disclosed by the companies.